A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
Lead Scientist at University of California Health
- Gregory Daniels, MD, PhD (ucsd)
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
- accepting new patients
- Start Date
- Completion Date
- Imugene Limited
- Imugene Limited (ASX: IMU) is a publicly-listed Australian biotechnology company developing cancer immunotherapies.
- Phase 1 research study
- Study Type
- Expecting 100 study participants
- Last Updated